{"id":"https://openalex.org/W4282958551","doi":"https://doi.org/10.1158/1538-7445.am2022-561","title":"Abstract 561: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy","display_name":"Abstract 561: CAR-targeted IL-2 drives selective CAR-T cell expansion and improves anti-tumor efficacy","publication_year":2022,"publication_date":"2022-06-15","ids":{"openalex":"https://openalex.org/W4282958551","doi":"https://doi.org/10.1158/1538-7445.am2022-561"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2022-561","doi":"https://doi.org/10.1158/1538-7445.am2022-561","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-561","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034167686","display_name":"Nathan D. Mathewson","orcid":"https://orcid.org/0000-0002-8895-2609","observed_orcids":["https://orcid.org/0000-0002-8895-2609"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nathan D. Mathewson","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043334947","display_name":"Kelly Dare Moynihan","orcid":"https://orcid.org/0000-0001-6200-7863","observed_orcids":["https://orcid.org/0000-0001-6200-7863"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kelly D. Moynihan","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052450833","display_name":"Sara Sleiman","orcid":"https://orcid.org/0009-0006-1922-4663","observed_orcids":["https://orcid.org/0009-0006-1922-4663"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara Sleiman","raw_affiliation_strings":["2University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wei Chen","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Chen","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061631253","display_name":"Paul H. Bessette","orcid":"https://orcid.org/0009-0003-8240-3304","observed_orcids":["https://orcid.org/0009-0003-8240-3304"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Bessette","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040386078","display_name":"Christopher R. Kimberlin","orcid":"https://orcid.org/0000-0001-9725-2447","observed_orcids":["https://orcid.org/0000-0001-9725-2447"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Kimberlin","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065353284","display_name":"Eric J. Wigton","orcid":"https://orcid.org/0000-0001-6111-9433","observed_orcids":["https://orcid.org/0000-0001-6111-9433"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Eric Wigton","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5082580626","display_name":"Danielle C. Pappas","orcid":"https://orcid.org/0000-0003-0412-3588","observed_orcids":["https://orcid.org/0000-0003-0412-3588"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Danielle Pappas","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089854506","display_name":"Terrence Park","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Terrence Park","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001016649","display_name":"Ton N. Schumacher","orcid":"https://orcid.org/0000-0003-0517-8804","observed_orcids":["https://orcid.org/0000-0003-0517-8804"]},"institutions":[{"id":"https://openalex.org/I2898336195","display_name":"The Netherlands Cancer Institute","ror":"https://ror.org/03xqtf034","country_code":"NL","type":"healthcare","lineage":["https://openalex.org/I2898336195"]}],"countries":["NL"],"is_corresponding":false,"raw_author_name":"Ton N. Schumacher","raw_affiliation_strings":["3Netherlands Cancer Institute, Amsterdam, Netherlands"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Netherlands Cancer Institute, Amsterdam, Netherlands","institution_ids":["https://openalex.org/I2898336195"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039491957","display_name":"Saar I. Gill","orcid":"https://orcid.org/0000-0001-7946-7778","observed_orcids":["https://orcid.org/0000-0001-7946-7778"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Saar I. Gill","raw_affiliation_strings":["2University of Pennsylvania, Philadelphia, PA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2University of Pennsylvania, Philadelphia, PA;","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005770383","display_name":"Yik Andy Yeung","orcid":"https://orcid.org/0009-0001-5435-6235","observed_orcids":["https://orcid.org/0009-0001-5435-6235"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yik Andy Yeung","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015404967","display_name":"Ivana M. Djuretic","orcid":"https://orcid.org/0009-0007-1094-3247","observed_orcids":["https://orcid.org/0009-0007-1094-3247"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ivana Djuretic","raw_affiliation_strings":["1Asher Biotherapeutics, Inc, South San Francisco, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Asher Biotherapeutics, Inc, South San Francisco, CA;","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"82","issue":"12_Supplement","first_page":"561","last_page":"561"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11491","display_name":"CAR-T cell therapy research","score":0.9984999895095825,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chimeric-antigen-receptor-t-cells","display_name":"chimeric antigen receptor T cells","score":0.7789999842643738},{"id":"https://openalex.org/keywords/il-2-mutein","display_name":"IL-2 mutein","score":0.7080000042915344},{"id":"https://openalex.org/keywords/stat5-signaling","display_name":"STAT5 signaling","score":0.8050000071525574},{"id":"https://openalex.org/keywords/car-t-cell-expansion","display_name":"CAR-T cell expansion","score":0.628000020980835},{"id":"https://openalex.org/keywords/car-t-cell-persistence","display_name":"CAR T cell persistence","score":0.7559999823570251},{"id":"https://openalex.org/keywords/antitumor-efficacy","display_name":"antitumor efficacy","score":0.703000009059906},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.4440000057220459},{"id":"https://openalex.org/keywords/il-2-toxicity","display_name":"IL-2 toxicity","score":0.5879999995231628},{"id":"https://openalex.org/keywords/nsg-mice","display_name":"NSG mice","score":0.3970000147819519}],"concepts":[{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.8616398572921753},{"id":"https://openalex.org/C2778957590","wikidata":"https://www.wikidata.org/wiki/Q798033","display_name":"CD19","level":3,"score":0.5474888682365417},{"id":"https://openalex.org/C2776090121","wikidata":"https://www.wikidata.org/wiki/Q193529","display_name":"T cell","level":3,"score":0.5401123762130737},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5328683853149414},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.46621257066726685},{"id":"https://openalex.org/C2778690821","wikidata":"https://www.wikidata.org/wiki/Q212354","display_name":"Cytokine","level":2,"score":0.4558502435684204},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.45427167415618896},{"id":"https://openalex.org/C2780850621","wikidata":"https://www.wikidata.org/wiki/Q3961647","display_name":"Cytokine release syndrome","level":5,"score":0.4238930344581604},{"id":"https://openalex.org/C2777371288","wikidata":"https://www.wikidata.org/wiki/Q410130","display_name":"Interleukin 2","level":3,"score":0.42140066623687744},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.40690892934799194},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.3558879494667053},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.334281861782074},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.29364854097366333},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.26352351903915405},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2022-561","doi":"https://doi.org/10.1158/1538-7445.am2022-561","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2022-561","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4379985091","https://openalex.org/W4405045130","https://openalex.org/W4310163379","https://openalex.org/W7130355866","https://openalex.org/W7171818402","https://openalex.org/W4403432961","https://openalex.org/W4410096192","https://openalex.org/W3212673191","https://openalex.org/W1967789051","https://openalex.org/W2017639055"],"abstract_inverted_index":{"Abstract":[0],"Chimeric":[1],"antigen":[2,188],"receptor":[3],"T":[4,216,297,303],"cell":[5,65,443],"(CAR-T)":[6],"therapies":[7,66],"have":[8,27,103],"transformed":[9],"the":[10,58,80,161,165,181,200,205,236,267,285,319,340,453],"treatment":[11,338],"of":[12,35,46,61,76,83,131,192,235,266,284,295,302,313,334,346,354,452],"some":[13],"hematological":[14],"malignancies":[15],"and":[16,33,52,79,138,147,154,197,281,331,370,374,401,445],"are":[17,37,129],"showing":[18],"promising":[19,391],"preliminary":[20],"results":[21],"in":[22,30,43,54,93,210,219,252,257,274,310,323,329,368,377,398],"solid":[23],"tumors.":[24],"Recent":[25],"studies":[26],"shown":[28,277],"that":[29,115,360],"vivo":[31,220,275,324],"expansion":[32,283,309,373,444],"persistence":[34],"CAR-Ts":[36,159,273,314,320,367],"correlated":[38],"with":[39,64,204,230,339,351],"improved":[40],"therapeutic":[41],"outcomes":[42],"patients.":[44],"Administration":[45],"IL-2":[47,62,78,86,112,127,140,156,174,363,380,439],"enhances":[48],"CAR-T":[49,96,110,172,195,289,335,372,396,442],"engraftment,":[50],"persistence,":[51],"functionality":[53],"preclinical":[55],"models.":[56],"However,":[57],"clinical":[59],"potential":[60],"stimulation":[63],"is":[67],"limited":[68],"using":[69,212,224],"current":[70],"molecules":[71,114,240,364,382],"due":[72],"to":[73,95,108,145,246,261,270,299,321,393],"severe":[74],"toxicity":[75],"high-dose":[77],"inadequate":[81],"selectivity":[82],"existing":[84],"engineered":[85,169],"variants":[87],"which":[88],"expand":[89,272],"multiple":[90],"endogenous":[91],"cells":[92,259],"addition":[94],"cells.":[97,125,217,263,336],"To":[98],"address":[99],"this":[100],"challenge,":[101],"we":[102],"applied":[104],"our":[105,361],"cis-targeting":[106],"technology":[107],"develop":[109],"selective":[111,173,332,441],"fusion":[113,133,268,381],"specifically":[116],"activate":[117,366],"CAR-Ts,":[118],"while":[119],"exhibiting":[120],"minimal":[121],"activity":[122,221,256,397],"on":[123,158],"CAR-negative":[124,262],"Cis-targeted":[126,379],"fusions":[128],"comprised":[130],"a":[132,135,279,306,390,399],"between":[134],"targeting":[136,166,191],"antibody":[137],"an":[139],"mutein":[141],"having":[142],"attenuated":[143,150],"binding":[144],"IL2R\u237a":[146],"IL2R\u03b2.":[148],"The":[149,218,233,264,288],"cytokine":[151],"selectively":[152,247,271,365],"binds":[153],"activates":[155],"receptors":[157],"via":[160],"avidity":[162],"provided":[163],"by":[164,243,384],"arm.":[167],"We":[168],"two":[170],"cis-targeted":[171,362],"fusions,":[175],"CAR-IL2":[176,179,237,341],"or":[177,238,386],"EGFRt-IL2.":[178],"targets":[180,199],"FMC63":[182],"CAR":[183],"directly":[184],"without":[185],"blocking":[186],"CD19":[187],"recognition,":[189],"enabling":[190],"approved":[193],"anti-CD19":[194],"products,":[196],"EGFRt-IL2":[198,239],"EGFRt":[201],"tag":[202],"co-expressed":[203],"CAR.":[206],"Molecules":[207],"were":[208],"characterized":[209],"vitro":[211,369],"primary":[213],"human":[214,231],"CAR-transduced":[215],"was":[222,241,276,315],"examined":[223],"tumor":[225,344],"bearing":[226],"NSG":[227],"mice":[228,349],"infused":[229,286,296,350],"CAR-Ts.":[232,287,355],"specificity":[234],"demonstrated":[242,316],"their":[244],"ability":[245,265],"induce":[248],"pSTAT5":[249],"signaling":[250],"resulting":[251],">1000-fold":[253],"preferential":[254],"STAT5":[255],"CAR-expressing":[258],"compared":[260],"proteins":[269],"through":[278],"substantial":[280],"specific":[282,400],"fraction":[290],"increased":[291],"from":[292],"approximately":[293],"50%":[294],"cells,":[298,304],"over":[300],"93%":[301],"demonstrating":[305],"nearly":[307],"40-fold":[308],"vivo.":[311,378],"Re-expansion":[312],"after":[317],"allowing":[318],"rest":[322],">100":[325],"days;":[326],"re-dosing":[327],"resulted":[328],"significant":[330],"re-expansion":[333],"Furthermore,":[337],"molecule":[342],"enhanced":[343,395],"regression":[345],"CD19+":[347],"lymphoma-bearing":[348],"suboptimal":[352],"doses":[353],"Together,":[356],"these":[357],"data":[358],"demonstrate":[359],"enhance":[371],"anti-tumor":[375,447],"efficacy":[376,448],"directed":[383],"anti-CAR":[385],"anti-tag":[387],"antibodies":[388],"represent":[389],"approach":[392],"confer":[394],"temporally":[402],"controlled":[403],"manner.":[404],"Citation":[405],"Format:":[406],"Nathan":[407],"D.":[408,411],"Mathewson,":[409],"Kelly":[410],"Moynihan,":[412],"Sara":[413],"Sleiman,":[414],"Wei":[415],"Chen,":[416],"Paul":[417],"Bessette,":[418],"Christopher":[419],"Kimberlin,":[420],"Eric":[421],"Wigton,":[422],"Danielle":[423],"Pappas,":[424],"Terrence":[425],"Park,":[426],"Ton":[427],"N.":[428],"Schumacher,":[429],"Saar":[430],"I.":[431],"Gill,":[432],"Yik":[433],"Andy":[434],"Yeung,":[435],"Ivana":[436],"Djuretic.":[437],"CAR-targeted":[438],"drives":[440],"improves":[446],"[abstract].":[449],"In:":[450],"Proceedings":[451],"American":[454],"Association":[455],"for":[456],"Cancer":[457,468],"Research":[458],"Annual":[459],"Meeting":[460],"2022;":[461],"2022":[462],"Apr":[463],"8-13.":[464],"Philadelphia":[465],"(PA):":[466],"AACR;":[467],"Res":[469],"2022;82(12_Suppl):Abstract":[470],"nr":[471],"561.":[472]},"counts_by_year":[{"year":2025,"cited_by_count":1}],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2022-06-17T00:00:00"}